NCI-H1650 / NCI-H1650-luc Orthotopic Mouse Model Service for Lung Cancer

The NCI-H1650 / NCI-H1650-luc orthotopic mouse model carries one of oncology's most instructive paradoxes — an EGFR exon 19 deletion that should make it exquisitely TKI-sensitive, undone by homozygous PTEN loss that keeps AKT phosphorylation stubbornly high — into the lung microenvironment where resistance biology and tumor angiogenesis can be interrogated together. Alfa Cytology delivers this NCI-60 reference line with genotype verification on every batch, intercostal orthotopic implantation or validated subcutaneous configurations, quantitative thoracic bioluminescence in vivo, and benchmark-validated combination arms — including published erlotinib–cisplatin and anti-angiogenic regimens — so your resistance-overcoming strategies are tested against the model the field itself uses to define the problem.

Overview of NCI-H1650 / NCI-H1650-luc Orthotopic Mouse Model for Lung Cancer

NCI-H1650 was established in 1987 in the NCI-Navy Medical Oncology Branch series from the pleural effusion of a 27-year-old White male smoker with bronchioloalveolar adenocarcinoma (stage IIIB), and it has been a member of the NCI-60 panel ever since — one of the most densely annotated cancer genomes in public pharmacogenomics. Its genetic logic is precise: an activating EGFR exon 19 deletion (delE746–A750) paired with homozygous loss of PTEN on a KRAS wild-type background. The consequence is the line's claim to fame: despite carrying the very mutation that predicts TKI response, H1650 shows primary relative resistance to erlotinib in vitro — phospho-AKT remains un-suppressed even when EGFR is inhibited, because PTEN loss uncouples the receptor from its downstream brake — and large-scale pharmacogenomic screens consistently flag it as refractory across first-, second-, and even third-generation EGFR inhibitors, including osimertinib.

Fig 1.Orthotopic xenograft showing that DGUOK knockout (KO2) suppressed the bioluminescence growth of luciferase-labeled H1650 tumors in the left lung of nude mice, with ex vivo imaging of left-lung primaries and right-lung local metastases confirming 75% inhibition of primary tumor growth and 91% inhibition of local metastasis by DGUOK depletion in H1650 cells. (Lin, Shengchen, et al., 2019)

That refractoriness has made H1650 the standard substrate for studying how to defeat innate TKI resistance. Combination therapy has been validated in vivo: erlotinib plus cisplatin inhibits H1650 xenograft growth and angiogenesis through suppression of c-MYC and HIF-1α, while the integrin-α2-downregulating anti-angiogenic agent E7820 (50 mg/kg) combined with erlotinib (60 mg/kg) produces synergistic antitumor activity accompanied by sharply reduced CD31 microvessel density and increased TUNEL-positive apoptosis of tumor-associated endothelium. Placed orthotopically by the intercostal technique, the model adds lung-specific stromal and vascular context to these readouts, and NCI-H1650-luc provides quantitative thoracic bioluminescence kinetics from the first week. Because HCC827 carries the identical EGFR deletion with PTEN intact and is correspondingly hypersensitive, the two lines form a matched within-study reference pair — the cleanest possible internal control for resistance-mechanism and combination-efficacy claims.

Cell Line Information: NCI-H1650 / NCI-H1650-luc

NCI-H1650 (ATCC CRL-5883; RRID CVCL_1483) is an adherent epithelial line that grows readily in vitro in RPMI-1640 with 10% fetal bovine serum, and its decade-spanning presence in the NCI-60 panel means that drug-response comparisons can be anchored to public datasets with unusual confidence. Every batch entering an in vivo program is genotype-verified for the EGFR exon 19 deletion and PTEN loss — the two lesions that define the model's behavior — and luciferase-tagged configurations are monoclonal, high-signal populations.

Our Services

Resistance studies are only as credible as the controls they carry. Alfa Cytology runs NCI-H1650 programs with the genotype verified on every batch, an optional HCC827 hypersensitive comparator arm inside the same study, benchmark combination regimens drawn from the published record, and angiogenesis endpoints — CD31 microvessel density, TUNEL, c-MYC, HIF-1α, and phospho-AKT — that connect tumor shrinkage to mechanism, all within one coordinated protocol from implantation to final report.

Workflow of NCI-H1650 / NCI-H1650-luc Orthotopic Mouse Model Construction

Orthotopic NCI-H1650 construction applies the validated intercostal microinjection framework, with study arms organized around resistance questions and benchmark combinations. The workflow below details model construction and execution from verified cell preparation through mechanism-anchored endpoints.

1. Cell Expansion and Genotype Verification: NCI-H1650 or NCI-H1650-luc cells are expanded in vitro in RPMI-1640 + 10% FBS to the logarithmic phase; batches are confirmed mycoplasma-negative, STR-authenticated, and verified for the EGFR exon 19 deletion and PTEN loss, with monoclonal luciferase expression confirmed for tagged lines.
2. Host Selection and Acclimatization: BALB/c nude, NOD-SCID, or NSG mice, typically 5–6 weeks of age, are acclimatized for approximately one week under SPF conditions; optional HCC827 comparator cohorts are prepared in parallel under identical handling.
3. Inoculum Preparation: Cells are washed in PBS and resuspended at high concentration (for example, 5 × 10⁷ cells/mL) with 1 mg/mL Matrigel, kept chilled; standard challenges are 10⁶ cells in 20 µL for intercostal implantation or 5 × 10⁶ cells for subcutaneous benchmarking.
4. Intercostal Implantation: Under isoflurane anesthesia, the left chest is opened through a small incision and a fine needle advanced approximately 3 mm through the intercostal space delivers 20 µL slowly into the lung parenchyma, with the needle held briefly on withdrawal to limit back-leakage.
5. Closure and Early Monitoring: The skin is closed with wound clips or sutures; animals recover on a warming platform with analgesia per IACUC protocol, and body weight plus respiratory status are monitored daily — weight decline emerging around day 10 serves as the sentinel of thoracic tumor growth.
6. Staging and Randomization: NCI-H1650-luc tumors are imaged by bioluminescence in vivo within the first week and weekly thereafter; subcutaneous arms are staged by caliper to approximately 200 mm³; animals are randomized to vehicle, single-agent TKI, and benchmark or investigational combination arms.
7. Treatment and Combination Scheduling: Test agents are dosed on study-defined schedules — erlotinib or next-generation EGFR inhibitors, platinum agents, anti-angiogenic partners such as integrin-α2 modulators — with published regimens available as reference arms and body weight monitored as a tolerability readout.
8. Endpoint Analysis and Reporting: At termination, thoracic or flank tumors are harvested and weighed; tissues are processed for CD31 immunohistochemistry (microvessel density), TUNEL staining (endothelial and tumor apoptosis), c-MYC, HIF-1α, phospho-AKT, and Ki-67; ex vivo bioluminescence maps signal distribution in luciferase studies; and tumor-growth inhibition, combination synergy, and survival data are compiled into the final report.

Fig 2. NCI-H1650 / NCI-H1650-luc orthotopic mouse model construction workflow.

Case Study-NCI-H1650 / NCI-H1650-luc Orthotopic Mouse Model Development

NCI-H1650 xenografts are the reference system for innate EGFR-TKI resistance, and the platform has carried a wide range of Alfa Cytology client programs — combination chemotherapy and anti-angiogenic strategies, PI3K-AKT reactivation studies, hypoxia and HIF-1α biology, and within-study comparator designs against PTEN-intact EGFR-mutant lines. Across these programs, readouts have combined imaging or caliper kinetics in vivo, CD31/TUNEL angiogenesis endpoints, and pathway-engagement immunohistochemistry. Anonymized case summaries and representative deliverable formats are available on request.

Why Choose Alfa Cytology?

NCI-H1650 is a model whose entire value lies in the precision of its genetics and the quality of its controls. Alfa Cytology has organized its service around both.

• The canonical EGFR exon 19-deleted, PTEN-null genotype — verified by sequencing on every study batch, so resistance claims rest on the right biology.
• NCI-60 pedigree with decades of public pharmacogenomic data anchoring every comparison your program will make.
• An optional HCC827 comparator arm carrying the identical EGFR deletion with intact PTEN, delivering an internal hypersensitive control within the same study.
• Benchmark-validated combination regimens from the published record, including erlotinib–cisplatin and anti-angiogenic schedules.
• Mechanism-anchored angiogenesis endpoints: CD31 microvessel density, TUNEL, c-MYC, HIF-1α, and phospho-AKT immunohistochemistry.
• Monoclonal, high-signal luciferase banks with quantitative thoracic bioluminescence in vivo from the first week.
• Flexible configurations spanning orthotopic intercostal implantation and subcutaneous benchmarking within one protocol.

Contact Us

If your EGFR program needs to confront innate resistance rather than assume sensitivity, the NCI-H1650 / NCI-H1650-luc orthotopic model is the definitive test system — and Alfa Cytology delivers it with the comparator arms and mechanistic endpoints that make results publishable. Contact us to discuss genotype verification, HCC827 comparator designs, and benchmark combination schedules, and receive a customized study quotation today.

For research use only. Not intended for any clinical use.